Correction: Toripalimab or placebo with chemotherapy as initial therapy for advanced nasopharyngeal carcinoma in a multicenter, randomized phase 3 trial

Category	Detail
Condition	Advanced nasopharyngeal carcinoma
Key Mechanisms	The correction reports no treatment mechanisms; it addresses errors and clarifications in a randomized phase 3 trial of toripalimab or placebo with chemotherapy.
Target Population	Patients enrolled in the multicenter randomized phase 3 trial of initial therapy for advanced nasopharyngeal carcinoma.
Care Setting	Correction to published trial results, tables, figures, and source data.

The corrected number of patients continuing maintenance treatment after chemotherapy is 233 (80.6%), not 231 (79.9%); the Extended Data Fig. 1 total is also 233.
The Fig. 2 data cutoff date is 18 February 2021, not 18 February 2020.
Corrected Toripalimab + GP safety values include any-grade thrombocytopenia in 92 (63.0%) and grade ≥3 hypochloremia in 2 (1.4%).
The Supplementary Table S10 footnote should read “determined by BIRC,” not “determined by investigator.”
Supplementary Table S13 reports Alive as 219 (75.8%), not 219 (76.1%); the Source Data Fig. 2 column should be labeled OS, not PFS.
In source data for Figs. 1, 2 and Extended Data Fig. 2, 0 denotes an event and 1 denotes censoring.
The correction states that the study results and conclusions are unaffected.

Trial participants with advanced nasopharyngeal carcinoma; the correction does not provide prescribing guidance.

The correction concerns toripalimab or placebo with chemotherapy and reports that the study results and conclusions remain unaffected.

Clinical Scorecard: Correction: Toripalimab or placebo with chemotherapy as initial therapy for advanced nasopharyngeal carcinoma